Back to Search
Start Over
High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.
- Source :
- Leukemia & Lymphoma; Jul2024, Vol. 65 Issue 7, p1020-1023, 4p
- Publication Year :
- 2024
-
Abstract
- This document presents data on the outcomes and toxicities of a treatment regimen for older adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). The study found that the treatment approach, which included induction chemotherapy with the addition of midostaurin, resulted in a high complete remission rate and a median overall survival of 9.3 months. Additionally, a significant number of patients underwent allogeneic hematopoietic stem cell transplantation (allo-HCT) with favorable outcomes. The authors conclude that this treatment approach is feasible and effective for older adults with FLT3-mutated AML. However, the study lacked long-term follow-up and data on minimal residual disease achievement and allo-HCT outcomes. [Extracted from the article]
- Subjects :
- ACUTE myeloid leukemia
OLDER patients
Subjects
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 65
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 178176894
- Full Text :
- https://doi.org/10.1080/10428194.2024.2332506